Pharmaceutical Online

The Building Blocks For Successful CDMO–Pharma Relationships For Packaging Operations To remain competitive, pharmaceutical manufacturers must secure cost-effective and environmentally responsible packaging through large vendor contracts and service agreements that ensure supply chain performance. By following a comprehensive system of best practices, both the pharma company and packaging manufacturer can achieve significant business growth. In this article, ANKITKUMAR PARMAR provides a thoughtful approach to quality service agreements. Read the full article: https://lnkd.in/e_j3BHGw #pharamceuticalpackaging #pharmaceuticalmanufacturing #packagingmanufacturing

Pharmaceutical Online Online is hosting "Opportunities For Innovation In GLP-1 and Peptide Manufacturing". Make sure to attend it on January 22, 2025. Register Here: https://lnkd.in/gqtKy8UG Ideal event for drug manufacturers such as Catalent Pharma Solutions, Novo Nordisk, Novartis, Merck, Roche, Eli Lilly and Company, Amgen, Viking Therapeutics, Inc., Metsera Panelists include Editor Tyler Menichiello, Chuck Olsen of NervGen Pharma Corp., Kevin Seibert of Eli Lilly and Company, Matteo Villain, Pharm.D. of CDMO Piramal Pharma Solutions This event is sponsored by Pharmaceutical Online

2024 Survey Findings: How Is The "Lab Of The Future" Becoming Reality? Pistoia Alliance conducted another Lab of the Future survey as a pulse check on which technologies the industry is investing in and its progress in integrating new tech into the lab. Among 200 life sciences R&D experts spanning Europe, the Americas, and APAC, the goal of the research is: What does the industry need to make the tech of tomorrow a reality in the labs of today? Learn more about the survey results: https://lnkd.in/eCpxF-zg

Are We Witnessing A New "Age Of The CDMO"? Across the life sciences industry, we are seeing the need for cost-effective solutions to ever more difficult development challenges that are growing in parallel with rising production costs. Over the past decade, pharmaceutical companies have increasingly outsourced development and manufacturing to CDMOs, shifting industry strategy and investment. This trend, supported by 2023 data, sees #CDMOs as crucial partners. The contract manufacturing market is projected to grow from $176 billion to $258 billion by 2028 within the $1.5 trillion global pharma industry, driven by both large and small companies seeking to optimize resources. In this article, Paul Cummings from PJC PHARMA CONSULTING LIMITED provides some insights into the primary factors driving this increased use of CDMOs. Read the full article: https://lnkd.in/ekzsraTD #contractmanfuacturing #pharmaceuticalmanufacturing

New facility construction gives builders the luxury of packing in the latest technology. AstraZeneca is making the most of that opportunity with its new #API facility for clinical and early commercial supply (APICOM) in Dublin. The new facility intensely focuses on data, including its capture, organization, and meaningful deployment at the heart of some of its most advanced technological fixtures. AstraZeneca’s Simon Capewell, head of operational technology and digital solutions at APICOM, recently spoke at the 2024 ISPE Pharma 4.0 and Annex 1 Conference about the specific technology they’re using and other aspects of the project. Learn more about AstraZeneca's project: https://lnkd.in/e8np9Pcu

Are you planning to expand your professional connections with pharma leaders? The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2025 gathers top-level management, key technical specialists, supply chain and procurement experts, and heads of pharma technology companies. The Congress is held on 14-15 April in Berlin, Germany. PHARMAP 2025 offers different formats of participation to help pharma professionals achieve their business goals: ●     delegates have access to all sessions and networking options; ●     speakers have an opportunity to present a case study to the audience; ●     exhibitors can showcase solutions to the pharma leaders; ●     sponsors have guaranteed B2B meetings with selected participants; ●     media partners have a chance to expose the brand to pharma professionals. To receive a personal proposal, fill in the form here: https://sh.bgs.group/25k #PHARMAP2025 #packaging #manufacturing

This presentation reviews the impact of cleaning and disinfectant residues in ATMP cGMP manufacturing, focusing on their risks and management. It addresses how Annex 1 revisions highlight the need for better residue control, offers methods to quantify residues beyond visual inspection, and discusses designing effective cleaning regimes. #ATMP #Annex1 #cGMP

FDA Issues New Guidance: Nonclinical Safety Assessment Of Oligonucleotide-Based Therapeutics FDA (CDER) issued a draft guidance in November 2024, Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics (ONT), to support clinical development and marketing of these products. As is customary, industry has 60 days to assess it and reply with feedback for consideration. This guidance should be considered with the also recently issued guidance by EMA2 on the development and manufacturing of oligonucleotide-based therapies to see that the two, although covering slightly different topics, are extremely complementary. In this article, Peter Calcott, Ph.D., FRSC, president and CEO of calcott consulting offers an overview of the guidance principles. https://lnkd.in/dd4k757X

The 4 Technologies Poised To Transform The Pharmaceutical Supply Chain In 2025 And Beyond In the coming decade, technological advancements like blockchain technology, sensor integration, robotics and automation in warehousing, and advanced planning tools are expected to significantly impact the pharmaceutical supply chain. In this article, Christopher Ohms discusses four technologies that promise to transform how pharmaceutical products are manufactured, tracked, stored, and distributed, ensuring that the supply chain remains resilient in the face of various challenges. Learn more: https://lnkd.in/eYYCvb4R